Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,858 SEK | +3,22% | +0,43% | -53,67% |
01/03 | Aandelen Sana Biotechnology stijgen na kleiner niet-GAAP nettoverlies in Q4 | MT |
01/03 | Sectorupdate: Gezondheidszorgaandelen randen hoger premarket vrijdag | MT |
Vakgebied
Aantal werknemers: 23
Verkoop per activiteit
SEK in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100,0
%
| 10 | 100,0 % | 15 | 100,0 % | +45,86% |
Verkoop per regio
SEK in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Other European Countries
75,4
%
| 8 | 76,1 % | 12 | 75,4 % | +44,49% |
Americas
24,6
%
| 3 | 23,9 % | 4 | 24,6 % | +50,16% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 66 | 01-01-11 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 01-01-11 |
Jørgen Drejer
FOU | Founder | 69 | 01-01-11 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 01-01-14 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 01-05-20 | |
Corporate Officer/Principal | 52 | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 01-01-11 |
Director/Board Member | 66 | 01-01-15 | |
Anna Ljung
BRD | Director/Board Member | 44 | 19-01-18 |
Director/Board Member | 58 | 01-01-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 132 529 086 | 80 887 377 ( 61,03 %) | 0 | 61,03 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Sector
Verkoop per regio
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-53,67% | 18,85 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |
- Beurs
- Aandelen
- Koers SANION
- Onderneming SANA AB